1-Propyl-5-MeO-AMT
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1-Propyl-5-MeO-AMT, also known as 1-propyl-5-methoxy-α-methyltryptamine, is a serotonin receptor modulator of the tryptamine, α-alkyltryptamine, and 5-methoxytryptamine families.[1][2][3] It is the 1-propyl derivative of 5-methoxy-α-methyltryptamine (5-MeO-AMT).[3]
| Clinical data | |
|---|---|
| Other names | 1-Propyl-5-MeO-DMT; 1-Pr-5-MeO-DMT; 1-Propyl-5-methoxy-α-methyltryptamine; N1-n-Propyl-5-methoxy-α-methyltryptamine |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor modulator |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·molâ1 |
| 3D model (JSmol) | |
| |
| |
Whereas most tryptamines are highly non-selective in terms of binding to serotonin receptors, 1-propyl-5-MeO-AMT shows selectivity for the serotonin 5-HT2A receptor.[1][2][3] Its affinities (Ki) for serotonin receptors were 12 nM for the serotonin 5-HT2A receptor, 120 nM for the serotonin 5-HT2C receptor, 5,000 nM for the serotonin 5-HT1B receptor, 7,100 nM for the serotonin 5-HT1A receptor, and >10,000 nM for the serotonin 5-HT1D receptor, whereas other serotonin receptors were not reported.[3] Its capacity and potency in activating the serotonin receptors was also not reported.[3]
The drug was developed by Richard Glennon and colleagues and was first described in 1990.[3] At the time, it was described as the most 5-HT2A receptor-selective tryptamine known to date.[3]
See also
- 1-Methyltryptamine
- 1-Methylpsilocin (1-methyl-4-HO-DMT)
- Lespedamine (1-methoxy-DMT)
- O-4310 (1-isopropyl-6-fluoro-4-HO-DMT)
- MLD-41 (1-methyl-LSD)
- Methysergide (1-methylmethylergometrine)